INNOVENT BIO

1801
83.9001.00% ( -0.850 )
Delay Closed: Nov 16, 16:08:11

Overview

INNOVENT BIO (1801)

Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republi...

Open
84.750
High
86.350
Low
82.950
Prev. Close
84.750
Volume
13.36M
Turnover
1.13B
Avg Price
84.429
Bid/Ask Ratio
8.24%
Amplitude
4.01%
52wk High
112.700
Volume Ratio
0.86
Turnover Ratio
0.76%
52wk Low
69.550
HK Mkt Cap
146.65B
Market CapHKD
146.65B
P/ETTM
103.35
P/EDynamic
50.82
P/EStatic
--
EPSTTM
0.812
EPSDynamic
1.65
EPSStatic
--
BVPS
13.67
P/B
6.14
HK Shares
1.75B
Dividend YieldTTM
--
DividendTTM
--
Shares
1.75B
Min lot size
500
Currency
HKD

INNOVENT BIO Analyst Rating

View more

Forecast & Rating

Nov 12, 2026
Price forecast
HK$130.3255.33%
Forecast & RatingStrong buy
29analysts
  • Strong buy68.97%
  • Buy24.14%
  • Hold6.90%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    Innovent Biologics closed down roughly 1% to HKD 83.90, with the morning session reaching a high of HKD 86.30 before afternoon weakness drove the stock below HKD 83.00, pressured by profit-taking and broader market weakness. Recent operational momentum remains strong: Q2 revenue reached HKD 4.977 billion, up 52.59% year-over-year, with net profit surging 58.32%, demonstrating sustained profitability gains. The company achieved significant milestones with seven innovative products successfully included in the 2026 National Reimbursement Drug List, alongside its GLP-1 product, while Zybrivo received a positive CHMP opinion for first-line lung cancer treatment, marking noteworthy international progress. Institutional support is evident, with Goldman Sachs recently raising its target price to HKD 122.28 and CLSA assigning a buy rating. However, the stock remains about 25% below its 52-week high of HKD 112.70, and at a P/E of 103.35, reflects elevated valuation levels where the market may be digesting elevated growth expectations.

  2. Nov, 13

    Innovent Bio declined 2.7% to close at HKD84.75 today, primarily driven by profit-taking following yesterday's sharp rally of over 7% combined with a technical pullback after recent substantial gains. However, underlying fundamentals remain solid: third-quarter product revenue surpassed RMB4.7 billion with year-over-year growth exceeding 40%, sustaining robust momentum from consecutive quarters each posting 50%+ revenue growth rates. The company continues to build out a pipeline spanning oncology, cardiovascular-metabolic, autoimmune and ophthalmology indications. Recent equity research catalysts have reinforced investor confidence: Goldman Sachs raised its price target to HKD122.28 based on Q3 product sales meeting expectations, while the majority of brokerages maintain buy-equivalent ratings. Management has articulated an ambitious target of RMB35-40 billion in total revenue by 2030, demonstrating conviction in sustained long-term growth. That said, valuation metrics appear stretched, with the P/E multiple standing at 104x. Notably, the stock has retreated 24.8% from its 52-week high of HKD112.7 and currently trades below its 60-day moving average of HKD93.84, suggesting near-term technical headwinds may persist.

  3. Nov, 12

    Xinda Bio closed up 0.3% at HKD 87.10 today, showing resilience amid a broader Hong Kong market decline of nearly 1%. Intraday trading displayed divergent sentiment: the morning session (09:30-11:59 BJ) gained 1.56% to HKD 87.65, peaking at HKD 88.55 at 11:00 BJ, but the afternoon session (13:00-16:00 BJ) retreated 0.85%, ultimately closing at HKD 87.10. The day's relative strength is underpinned by robust recent earnings: Q2 revenue grew 52.6% year-over-year to HKD 4.977 billion, net profit surged 58.3% to HKD 724 million, and EPS expanded 50.6% to HKD 0.4043, underscoring strong momentum in innovative drug commercialization. From a price positioning perspective, the stock has gained 10.5% year-to-date and currently trades 22.7% below its 52-week high of HKD 112.70, with the 20-day moving average at HKD 84.64 serving as technical support. However, the elevated P/E ratio of 107.3 signals that market expectations for growth have already been substantially incorporated into valuations, and ongoing broader market weakness may limit near-term upside potential.

  4. Nov, 11

    Innovent Bio declined 1.7% to close at HKD 86.8 today, in line with broader Hong Kong market weakness (HSI down nearly 1%). The stock touched an intraday low of HKD 85.2 at 10:56 AM before recovering to close in the afternoon. Despite Goldman Sachs raising its price target to HKD 122.28 recently and Q3 product sales surpassing RMB 470 million with over 40% year-over-year growth, the company still faced selling pressure. Recent interim financials remain robust: Q2 2026 revenue reached HKD 4.977 billion (up 52.59% YoY) and net profit HKD 724 million (up 58.32% YoY) with EPS of HKD 0.4043. However, the stock has retreated 22.98% from its 52-week high of HKD 112.7 set on August 25, currently trading at a P/E of 106.92, suggesting valuations remain stretched. Today's pullback appears reflective of profit-taking rather than fundamental deterioration, as market pricing has likely already factored in substantial near-term growth.

  5. Nov, 10

    Innovent Bio advanced approximately 2.1% to close at HKD 88.3 today, primarily driven by clinical trial progress and robust quarterly earnings. The flagship product Sintbilo achieved primary endpoints in a Phase 3 cholesterol trial, providing a key catalyst for the company's innovation pipeline. Q3 product revenue surged to over RMB 4.7 billion with year-over-year growth exceeding 40%, translating to quarterly EPS of 0.4043 HKD, up 51% YoY. On institutional support, Goldman Sachs recently elevated its price target to HKD 122.28, bolstering market confidence. The broader pipeline is progressing well, with multiple assets including the lung cancer combination therapy IBI363 and the first-in-class bispecific antibody IBI3001 delivering positive clinical readouts. From a valuation perspective, the stock is up 12% year-to-date and trades approximately 22% below its 52-week high of 112.7 HKD. While the current PE multiple of 108.77x appears elevated, it appears supported by the company's robust 50%+ revenue growth and 58% net profit growth on a year-over-year basis.

News

Bullish vs. Bearish — Last 3 Months

14.0k followers · 0 opinions
▲Bullish50%
50%Bearish▼